MeiraGTx LLC

MeiraGTx's AAV-GAD gene therapy for Parkinson's disease met primary endpoints in a Phase I/II trial, showing significant improvements in motor scores and quality of life, with no adverse events reported.

MeiraGTx's gene therapy (AAV-GAD) for Parkinson’s disease passed midphase trial, showing significant improvement in PDQ-39 scores at 26 weeks with high-dose treatment, and is now in discussion for Phase III. AAV-GAD was safe and well-tolerated, with no SAEs related to treatment.

MeiraGTx's AAV-GAD gene therapy for Parkinson's disease showed significant safety and efficacy in a small phase 1/2 study, prompting plans for a pivotal trial. The therapy, administered via subthalamic nucleus infusion, demonstrated clinically meaningful improvements in motor function and quality of life scores.

Pfizer pays Triana Biomedicines $49M for molecular glue degrader research; Tim Buckley joins Pfizer's board amid Starboard Value pressure; Jazz Pharmaceuticals' Zepzelca and Roche's Tecentriq combo outperforms Tecentriq alone in small cell lung cancer; MeiraGTx's Parkinson's gene therapy shows promise in small trial; Akeso raises $250M for global antibody drug trials; Inventiva gets $100M funding with Mark Pruzanski as chairman.